REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options and Restricted Stock Units

MaxCyteAnnouncement

18/10/2024 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241018:nRSR7726Ia&default-theme=true

RNS Number : 7726I  MaxCyte, Inc.  18 October 2024

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Grant of Options and Restricted Stock Units

 

ROCKVILLE, MD, October 18, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT),
a leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and to support innovative, cell-based
research, announces that on 14 October 2024, Cynthia Collins, a non-executive
director, has been granted total of 97,698 options ("Option Grant") in respect
of common stock in the Company ("Common Stock"), and 51,679 restricted stock
units ("RSU"s), which were agreed in September pursuant to Cynthia's
appointment.

 

The Option Grant vests over three (3) years, with the initial vesting of
1/3(rd) of the total after twelve (12) months, and the remainder vesting
monthly over the following 24 months.  The Option Grant have an exercise
period of 10 years from date of grant, at which time they will expire, and
have an exercise price equal to the closing price of MaxCyte's stock on 14
October 2024, of $3.87 on the United States Nasdaq Stock Exchange.

 

The RSUs vest at the end of twelve (12) months after date of grant.  (1 year
cliff until fully vested).

 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology, as
well as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Liberum                               +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 ICR Consilium                                 maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Mary-Jane Elliott

 Chris Welsh

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Cynthia Collins

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte, Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Grant of options of common stock

 c)   Price(s) and volume(s)                                       97,698 Options at an exercise price of $3.87

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      14 October 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Cynthia Collins

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte, Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Grant of restricted stock units

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Grant of options of restricted stock units

 c)   Price(s) and volume(s)                                       51,679 restricted stock units, price N/A

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      14 October 2024

 f)   Place of the transaction                                     US Stock Exchange, Nasdaq

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGIBDGBDBDGSI